A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine
- 1 February 2022
- journal article
- letter
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 42 (3) , 324-325
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months reportBrain, Behavior, & Immunity - Health, 2021
- COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapineJournal of Psychiatry and Neuroscience, 2021
- Clozapine in the Time of COVID-19Clinical Psychopharmacology and Neuroscience, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studiesPsychological Medicine, 2019
- Meta‐analysis examining the epidemiology of clozapine‐associated neutropeniaActa Psychiatrica Scandinavica, 2018
- Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapineTherapeutic Advances in Drug Safety, 2018
- Clozapinev. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysisThe British Journal of Psychiatry, 2016
- Worldwide Differences in Regulations of Clozapine UseCNS Drugs, 2016
- Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell MonitoringAnnals of Pharmacotherapy, 2006